Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta reported its Q4 and FY 2024 results, highlighting a 4% revenue growth in Sample Management Solutions and Multiomics. The company anticipates a 3%-5% organic revenue growth for FY 2025 and a 300 basis points EBITDA margin expansion. For Q4, revenue was $170 million, down 1% YoY, with a 2% organic decline. Sample Management Solutions and Multiomics grew by 5% and 8% organically, respectively, while B Medical Systems saw a 35% decline. FY 2024 revenue was $656 million, down 1% YoY, driven by a 27% decline in B Medical Systems revenue. The company reported an operating loss of $201 million for FY 2024, with a non-GAAP diluted EPS of $0.41. Azenta plans to sell B Medical Systems to focus on core businesses and appointed Lawrence Y. Lin as the new CFO. They ended FY 2024 with $522 million in cash and equivalents and repurchased 4.9 million shares worth $249 million in Q4.
Azenta (Nasdaq: AZTA) has scheduled its fiscal fourth quarter and full year 2024 earnings announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results for the period ended September 30, 2024. A replay of the webcast will be available starting at 8:30 a.m. ET on November 13, 2024.
Azenta (NASDAQ: AZTA) has appointed three new independent directors to its Board: William Cornog (former head of KKR Capstone), Quentin Koffey (Founder of Politan Capital Management, owning 9.4% of Azenta), and Alan Malus (former Executive VP of Thermo Fisher). The company established a new Value Creation Committee to focus on long-term value creation, growth initiatives, and capital deployment. The committee will be chaired by William Cornog and includes the new directors along with CEO John Marotta and current director Martin Madaus. Azenta has also reaffirmed its full-year 2024 financial guidance previously announced on August 6th, 2024.
Azenta (Nasdaq: AZTA) has become the first commercial provider to receive regulatory approval for a clinical long-read Whole Genome Sequencing (WGS) test in the United States. The test, utilizing PacBio's Revio sequencer for HiFi sequencing, is performed in GENEWIZ's CLIA-certified and CAP-accredited clinical genomics laboratory. This breakthrough enables precise detection of complex genomic alterations associated with rare diseases that are typically undetectable through traditional short-read sequencing methods. The technology provides comprehensive genome analysis by capturing long DNA stretches in single reads, enhancing diagnostic accuracy for rare diseases.
Azenta, Inc. (Nasdaq: AZTA) has announced a significant leadership change. John P. Marotta will join as President and CEO on September 9, 2024, succeeding retiring Dr. Stephen Schwartz. Marotta brings two decades of experience in life sciences, medical devices, and diagnostics. He joins from Patient Square Capital and previously served as CEO of PHC Holdings The appointment follows a rigorous search process led by the Board. Frank E. Casal, Chairman of Azenta's Board, expressed confidence in Marotta's ability to lead the company's next growth phase. Dr. Schwartz, who led Azenta for 14 years, will remain as an advisor to ensure a smooth transition.
Azenta's GENEWIZ is celebrating its 25th anniversary with the launch of GENEWIZ Week from September 16-20, 2024. This event showcases GENEWIZ's commitment to advancing scientific discoveries through cutting-edge solutions. The week-long celebration includes:
- Virtual workshops followed by interactive expert roundtables
- An awards program offering $50,000 in research funding
- Engaging promotions and giveaways
The event aims to support researchers in overcoming challenges and streamlining their work. Ginger Zhou, SVP & GM of GENEWIZ Multiomics and Synthesis Solutions, emphasized the company's dedication to providing tools and support for significant scientific discoveries. Registration for GENEWIZ Week 2024 is now open, offering researchers opportunities for learning, networking, and celebration.
Azenta (Nasdaq: AZTA) reported its third-quarter results for fiscal 2024, ending June 30, 2024. The company achieved revenue of $173 million, up 4% YoY, driven by growth in Sample Management Solutions and B Medical Systems. Organic revenue grew by 5% YoY. Non-GAAP diluted EPS from continuing operations increased to $0.16 from $0.13. Adjusted EBITDA rose 39% to $18 million, with a margin of 10.3%. The company repurchased 4.2 million shares for $225.9 million. Azenta revised its FY2024 guidance, lowering revenue expectations to $652-$658 million but raising earnings guidance to $0.30-$0.36 per share. Operating cash flow was $2 million, and the company had $754 million in cash and equivalents at the quarter's end. The company will host an earnings call, accessible on its investor relations website.
Azenta (Nasdaq: AZTA) has announced its participation in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The event is scheduled for Monday, August 12, 2024. This conference provides a platform for companies in the medical technology and diagnostics sectors to engage with investors and industry professionals.
The virtual format of the conference allows for efficient one-on-one meetings between company management and attendees. Azenta's participation suggests its commitment to maintaining investor relations and showcasing its position in the MedTech and diagnostics markets. This event could offer insights into Azenta's strategies, recent developments, and future outlook in the rapidly evolving healthcare technology landscape.
Azenta (Nasdaq: AZTA) is set to announce its fiscal third quarter 2024 earnings on Tuesday, August 6, 2024, after the market closes. The earnings pertain to the quarter ending on June 30, 2024. The company will also host a conference call and live webcast to discuss the financial results at 4:30 p.m. Eastern Time on the same day. Interested parties, including analysts, investors, and media, can access the live webcast through the Azenta website. Additionally, a replay of the webcast will be available starting at 8:30 a.m. ET on August 7, 2024.
Azenta (Nasdaq: AZTA) has announced its participation in the FinnGen project, a large-scale personalized medicine initiative in Finland. Azenta will provide proteomics profiling for up to 20,000 individuals out of the 500,000 Finnish biobank participants in the study. The company will use Olink's advanced proteomics technology to deliver high-quality protein-level measurements across major biological pathways.
This collaboration with the University of Helsinki aims to integrate proteomics insights with extensive genomic data, potentially leading to a deeper understanding of disease mechanisms, new biomarkers for early detection, and novel therapeutic targets. Azenta's involvement underscores its commitment to advancing healthcare innovation and personalized treatments.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
